Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 3/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | PPP1CC | P36873 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080046 | 0.86 | PPM1B (0.84) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL18235530 | 0.78 | PPM1B (0.72) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL13338808 | 0.78 | PPM1B (0.67) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL26613051 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL8758857 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL9460572 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL2332679 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL15590874 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL390763 | 0.78 | PPM1B (1.00) | PPM1BPTPN1PPP1CCKDM4EGMNN | |
| SCHEMBL15172570 | 0.77 | PPM1B (0.65) | PPM1BPTPN1PPP1CCKDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | PPM1B 1223/4885PTPN1 3527/4885PPP1CC 2230/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | PPM1B 1595/4885PTPN1 2259/4885PPP1CC 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.